1. Home
  2. SFM vs DFTX Comparison

SFM vs DFTX Comparison

Compare SFM & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprouts Farmers Market Inc.

SFM

Sprouts Farmers Market Inc.

N/A

Current Price

$71.94

Market Cap

7.0B

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$37.63

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SFM
DFTX
Founded
2002
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
5.9B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
SFM
DFTX
Price
$71.94
$37.63
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$98.89
$38.50
AVG Volume (30 Days)
1.7M
1.9M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
41.60
N/A
EPS
3.08
N/A
Revenue
$8,806,159,000.00
N/A
Revenue This Year
$8.95
N/A
Revenue Next Year
$7.36
N/A
P/E Ratio
$23.85
N/A
Revenue Growth
14.08
N/A
52 Week Low
$64.75
$14.62
52 Week High
$127.91
$49.70

Technical Indicators

Market Signals
Indicator
SFM
DFTX
Relative Strength Index (RSI) 38.83 37.39
Support Level $72.37 $16.37
Resistance Level $80.46 $49.13
Average True Range (ATR) 3.55 2.02
MACD -0.86 -0.31
Stochastic Oscillator 12.76 0.54

Price Performance

Historical Comparison
SFM
DFTX

About SFM Sprouts Farmers Market Inc.

Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: